Concurrent involved field radiation therapy and temsirolimus in refractory mantle cell lymphoma (MCL).
Kirova
Youlia M
YM
Department of Radiation Oncology, Institut Curie, 26 rue d’Ulm, Paris, France. youlia.kirova@curie.net
Chargari
Cyrus
C
Amessis
Malika
M
Vernant
Jean-Paul
JP
Dhedin
Nathalie
N
D000970:Antineoplastic Agents / Q000009:adverse effects; D036101:Cord Blood Stem Cell Transplantation; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy / Q000379:methods; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C401859:temsirolimus; D020123:Sirolimus